About this content About Sean Mason Sean Mason is a Senior Journalist at Proactive, having researched and written about Canadian and US equities for 20 years. Sean graduated from the University of Toronto with a BA in history and economics and has also passed the Canadian Securities Course. He previously worked at Investors Digest of Canada, Stockhouse, and SmallCapPower.com. Read more About the publisher Proactive financial news and online broadcast teams provide fast, accessible, informative and action ...

Moderna Inc.’s stock soared 10% Tuesday to lead S&P 500 index gainers, after Oppenheimer upgraded the stock to the equivalent of buy and said it expects the biotech to have five products approved by 2026.Analysts led by Hartaj Singh upgraded the stock MRNA, +11.61% to outperform from perform and said it expects it to perform better this year than the dismal showing recorded in 2023. The company currently has just one approved product, its mRNA-based COVID-19 vaccine, which has already passed peak sales. Bu ...

Moderna stock was one of the worst performers in the S&P 500 last year as Covid-19 vaccine sales tumbled, but the vaccine maker has more to offer, according to Oppenheimer analysts. ...

Stocks have had a banner year, but two Covid-era heroes were left in the dust. Analysts think that could change in 2024. ...

Key Points Industry/Company - **Company**: Moderna, Inc. (NASDAQ:MRNA) - **Industry**: Biotechnology, mRNA medicine Core Points and Evidence - **Mission**: To deliver the greatest possible impact to people through mRNA medicine. - **Platform**: Moderna's mRNA platform allows for the creation of multiple medicines for various diseases. - **Pipeline**: Several medicines in development for 2024 and 2025, including vaccines, cancer, and rare genetic diseases. - **Disease X**: Moderna is preparing for a potential next pandemic with mRNA access, a tool to create an ecosystem for collaboration with scientists worldwide. - **Environmental Goals**: Net zero carbon emissions for Scope 1 and 2 by 2030. - **Employee Focus**: Attracting and retaining top talent, fostering a diverse and inclusive culture, and providing employee benefits and development opportunities. - **Community Engagement**: Employee volunteering programs, philanthropic giving, and partnerships with NGOs. - **Governance and Ethics**: Strong governance practices, ethical business conduct, and transparency in ESG reporting. Other Important Points - **Rare Diseases**: Moderna's mRNA platform has shown promise in treating rare diseases, with several programs demonstrating positive results. - **Health Equity**: Moderna is committed to inclusive research and ensuring that clinical trials represent diverse populations. - **Pandemic Preparedness**: Moderna's mRNA platform has been instrumental in developing the COVID-19 vaccine and is being used to prepare for future pandemics. - **Global Health Portfolio**: Includes vaccines for COVID-19, Zika, Chikungunya, HIV, and pandemic influenza. - **mRNA Access Program**: Collaborates with academic institutions worldwide to develop mRNA vaccines against emerging and neglected infectious diseases. - **Sustainability**: Moderna is committed to sustainability by design, resource conservation, and decarbonizing its value chain. - **Employee Engagement**: Moderna focuses on employee engagement, culture, and well-being through various programs and initiatives. - **Community Impact**: Moderna's community programs focus on education, health, and social justice. - **Governance**: Moderna's board of directors and executive committee are committed to ESG oversight and accountability. References - [doc id='3'] - [doc id='5'] - [doc id='7'] - [doc id='8'] - [doc id='9'] - [doc id='10'] - [doc id='12'] - [doc id='13'] - [doc id='14'] - [doc id='15'] - [doc id='16'] - [doc id='17'] - [doc id='18'] - [doc id='19'] - [doc id='20'] - [doc id='21'] - [doc id='22'] - [doc id='23'] - [doc id='24'] - [doc id='25'] - [doc id='26'] - [doc id='27'] - [doc id='28'] - [doc id='29'] - [doc id='30'] - [doc id='31'] - [doc id='32'] - [doc id='33'] - [doc id='34'] - [doc id='35'] - [doc id='36'] - [doc id='37'] - [doc id='38'] - [doc id='39'] - [doc id='40'] - [doc id='41'] - [doc id='42'] - [doc id='43'] - [doc id='44'] - [doc id='45'] - [doc id='46'] - [doc id='47'] - [doc id='48'] - [doc id='49'] - [doc id='50'] - [doc id='51'] - [doc id='52'] - [doc id='53'] - [doc id='54'] - [doc id='55'] - [doc id='56'] - [doc id='57'] - [doc id='58'] - [doc id='59'] - [doc id='60'] - [doc id='61'] - [doc id='62'] - [doc id='63'] - [doc id='64'] - [doc id='65'] - [doc id='66'] - [doc id='67'] - [doc id='68'] - [doc id='69'] - [doc id='70'] - [doc id='71'] - [doc id='72'] - [doc id='73'] - [doc id='74'] - [doc id='75'] - [doc id='76'] - [doc id='77'] - [doc id='78'] - [doc id='79'] - [doc id='80'] - [doc id='81'] - [doc id='82'] - [doc id='83'] - [doc id='84'] - [doc id='85'] - [doc id='86'] - [doc id='87'] - [doc id='88'] - [doc id='89'] - [doc id='90'] - [doc id='91'] - [doc id='92'] - [doc id='93'] - [doc id='94'] - [doc id='95'] - [doc id='96'] - [doc id='97'] - [doc id='98'] - [doc id='99'] - [doc id='100'] - [doc id='101'] - [doc id='102'] - [doc id='103'] - [doc id='104'] - [doc id='105'] - [doc id='106'] - [doc id='107'] - [doc id='108'] - [doc id='109'] - [doc id='110'] - [doc id='111'] - [doc id='112'] - [doc id='113'] - [doc id='114'] - [doc id='115'] - [doc id='116'] - [doc id='117'] - [doc id='118'] - [doc id='119'] - [doc id='120'] - [doc id='121'] - [doc id='122'] - [doc id='123'] - [doc id='124'] - [doc id='125'] - [doc id='126'] - [doc id='127']

Moderna, Inc. (NASDAQ:MRNA) 35th Annual Piper Sandler Healthcare Conference November 30, 2023 12:30 PM ET Company Participants Jamey Mock - CFO Conference Call Participants Ted Tenthoff - Piper Sandler Ted Tenthoff My name is Ted Tenthoff. I'm a senior biotech analyst at Piper Sandler. And before I begin our next presentation, I'm required to point out certain disclosures regarding the relationship between Piper and our next presenting company, Moderna, which are located both at the back of the room and als ...

Moderna, Inc. (NASDAQ:MRNA) 2023 Jefferies London Healthcare Conference November 16, 2023 3:30 AM ET Company Participants Lavina Talukdar - Senior Vice president of Investor Relations Unidentified Analyst Good morning everyone. Thank you for joining us here on our opening morning session for Moderna. Up here with me on the stage I have Senior Vice president of Investor Relations, Lavina Talukdar. Lavina, I would love to just maybe start coming away from third quarter earnings. The company provided some new ...

Moderna, Inc. (NASDAQ:MRNA) Second Digital Investor Event November 8, 2023 8:00 AM ET Company Participants Lavina Talukdar - Head of IR Stephane Bancel - CEO Brad Miller - Chief Information Officer Dave Johnson - Chief Data and Artificial Intelligence Officer Wenhao Liu - Director of Software Engineering Brice Challamel - Empowerment VP Conference Call Participants Hartaj Singh - Oppenheimer & Co. Jasmine Fels - UBS Jessica Fye - JP Morgan Lavina Talukdar Good morning, everyone, and welcome to Moderna's Se ...

Moderna, Inc. (NASDAQ:MRNA) Q3 2023 Earnings Conference Call November 2, 2023 8:00 AM ET Company Participants Lavina Talukdar - Head of Investor Relations St??phane Bancel - Chief Executive Officer Arpa Garay - Chief Commercial Officer Jamey Mock - Chief Financial Officer Stephen Hoge - President Conference Call Participants Gena Wang - Barclays Salveen Richter - Goldman Sachs Terence Flynn - Morgan Stanley Jessica Fye - JPMorgan Luca Issi - RBC Capital Hartaj Singh - Oppenheimer Evan Wang - Guggenheim Secu ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _ to _ Commission File Number: 001-38753 Moderna, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 81-3467528 (State or Other Jurisdicti ...